Media Newsroom of

Epygenix Therapeutics, Inc.

140 E. Ridgewood Ave (Suite 415 South Tower)
Paramus, NJ 07652

About Epygenix Therapeutics, Inc.

Epygenix Therapeutics, Inc. is a precision medicine-based biopharmaceutical company focused on discovering and developing drugs to treat rare and intractable genetic epilepsy in childhood, such as Dravet Syndrome.

Recent Press Releases of Epygenix Therapeutics, Inc.

Epygenix Therapeutics Announces First Patient Successfully Dosed in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100

Epygenix Therapeutics Announces First Patient Successfully Dosed in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100

Nov 12, 2020 - Epygenix Therapeutics, Inc. (Press Release) - Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing precision medicine for Dravet Syndrome, announced today that the first patient has been successfully dosed in a Phase 2, 20-week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 as Adjunctive Therapy in Children with Dravet Syndrome. This study will evaluate the efficacy and safety…

Epygenix Therapeutics Announces First Patient Enrolled in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100

Epygenix Therapeutics Announces First Patient Enrolled in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100

Oct 02, 2020 - Epygenix Therapeutics, Inc. (Press Release) - Epygenix Therapeutics, Inc., a privately-held biopharmaceutical company developing precision medicine for Dravet Syndrome, announced today that the first patient has been enrolled in a Phase 2, 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Trial of EPX-100 as Adjunctive Therapy…

Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100

Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100

Sep 17, 2020 - Epygenix Therapeutics, Inc. (Press Release) - Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing precision medicine for Dravet Syndrome, announced today that the Company initiated a Phase 2, 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Trial of EPX-100 as Adjunctive Therapy in Children with…

Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome

Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome

Jun 24, 2019 - Epygenix Therapeutics, Inc. (Press Release) - ​​​Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing precision medicines for Dravet Syndrome, announced today that the Company has submitted Investigational New Drug Application (IND) and Fast Track Designation Request for EPX-100 to the U.S. Food and Drug Administration…

Epygenix Therapeutics Receives US FDA Orphan Drug Designation for EPX-300 for the Treatment of Patients With Dravet Syndrome

Epygenix Therapeutics Receives US FDA Orphan Drug Designation for EPX-300 for the Treatment of Patients With Dravet Syndrome

Aug 23, 2017 - Epygenix Therapeutics, Inc. (Press Release) - Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing precision medicine for rare and catastrophic forms of genetic epilepsy, announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation for EPX-300 for the treatment of patients…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Already have an account ? Login

Reset Password

Already have an account ? Login